U.S. Court in Hawaii Finds Mifepristone Safety Restrictions Unlawful, Remands to FDA for Further Consideration
- November 07, 2025
A federal district court in Hawaii found additional safety restrictions that the Food and Drug Administration (FDA) placed on the abortion pill mifepristone were arbitrary and capricious in violation of the Administrative Procedure Act (APA). However, the U.S. District Court for the District of Hawaii left the 2023 Risk Evaluation and Mitigation Strategy (REMS) for mifepristone in place and remanded to the FDA for further consideration of the issues raised in the lawsuit.
ARTICLE TAGS
You must be logged in to access this content.